Anti-Tumour Activity of Bisphosphonates in Human Myeloma Cells
- 1 January 1998
- journal article
- review article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 32 (1-2), 129-138
- https://doi.org/10.3109/10428199809059253
Abstract
Multiple myeloma is a haematological malignancy characterized by an expansion of malignant plasma cells within the bone marrow and is frequently associated with bone disease involving the development of osteolytic bone lesions, pathological fractures, osteoporosis and hypercalcaemia. A class of anti-resorptive drugs known as bisphosphonates have been in use to treat osteoclast-mediated bone diseases for the past 3 decades, and are currently proving effective in the treatment of the bone disease associated with multiple myeloma. Recent studies have suggested that bisphosphonate treatment may also result in an improvement in survival in some patients with multiple myeloma. These effects on survival may reflect an indirect effect of the bisphosphonates on tumour growth, via inhibition of osteoclast activity and hence a reduction in the release of tumour growth factors. However, it is also possible that bisphosphonates may have a direct effect on myeloma cells. In support of this we have demonstrated that bisphosphonates can decrease cell proliferation and induce apoptosis in human myeloma cells in vitro, and this review discusses the possibility that bisphosphonates may have not only an anti-resorptive action, but may also have a direct anti-tumour activity.Keywords
This publication has 43 references indexed in Scilit:
- Excessive bone resorption in human plasmacytomas: direct induction by tumour cells in vivoBritish Journal of Haematology, 1995
- Randomised, placebo-controlled multicentre trial of clodronate in multiple myelomaThe Lancet, 1992
- Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorptionEuropean Journal of Haematology, 1992
- Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma.JCI Insight, 1991
- Micro‐osteoclast resorption as a characteristic feature of B‐cell malignancies other than multiple myelomaBritish Journal of Haematology, 1990
- Production of interleukin-1 by bone marrow myeloma cellsBlood, 1989
- Production of Lymphotoxin, a Bone-Resorbing Cytokine, by Cultured Human Myeloma CellsNew England Journal of Medicine, 1987
- Quantitative histology of myeloma‐induced bone changesBritish Journal of Haematology, 1982
- Evidence for the Secretion of an Osteoclast Stimulating Factor in MyelomaNew England Journal of Medicine, 1974
- Bone-Resorbing Activity in Supernatants from Lymphoid Cell LinesNew England Journal of Medicine, 1974